To review and discuss the spectrum of adverse events caused by antipsychotic agents that can directly influence the outcome of treatment by interfering with patient acceptance of and adherence to therapy.
Method:
The adverse effects of traditional and second-generation antipsychotic medications were discussed during a series of clinical workshops attended by psychiatrists from across Canada. The various adverse effects of antipsychotic drugs as well as their assessment and management are reviewed.
Results:
Simple techniques for assessing adverse effects such as extrapyrimidal symptoms (EPS) are described. In some cases, adverse effects can be managed by dosage reduction and/or the use of adjunctive therapies such as antiparkinsonian agents and benzodiazepines. However, in some patients dose reduction carries the risk of symptom reemergence, while the commonly used adjunctive medications are associated with adverse effects of their own.
Conclusions:
Treatment-related side effects often require a reduction in dosage or a change in medication. Proper management can help encourage patient compliance and improve the outcome of antipsychotic treatment. The availability of the newer atypical antipsychotics offers another alternative, because they are associated with a much lower incidence of antipsychotic-induced side effects.
BorisonRL. The role of cognition in the risk-benefit and safety analysis of antipsychotic medication. Acta Psychiatr Scand1996;94(389 Suppl):5S–11S.
2.
FinkEBBradenWQuailsCB. Predicting pharmacotherapy outcome by subjective response. J Clin Psychiatry1982;43:272–5.
3.
HogeSKApplebaumPSLawlorTBeckJCLitmanRGreerA, and others. A prospective, multicenter study of patients' refusal of antipsychotic medication. Arch Gen Psychiatry1990;47:949–56.
4.
WeidenPHarriganM.A clinical guide for diagnosing and managing patients with drug-induced dysphagia. Hosp Commun Psychiatry1986;37:396–8.
5.
GurRE. Left hemisphere dysfunction and left hemisphere overactivation in schizophrenia. J Abnorm Psychol1978;87:226–78.
6.
ReynoldsGP. Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia. Nature1983;305:527–9.
7.
BrachaHS. Asymmetric rotational (circling) behaviour, a dopamine-related asymmetry: Preliminary findings in unmedicated and never-medicated schizophrenic patients. Biol Psychiatry1987;22:995–1003.
8.
McCarleyRWFauxSFShentonMLe MayMCaneMBallingerR, and others. CT abnormalities in schizophrenia. A preliminary study of their correlations with P300/P200 electrophysiological features and positive/negative symptoms. Arch Gen Psychiatry1989;46:698–708.
9.
ChouinardGRoss-ChouinardAAnnableLJonesBD. The Extrapyramidal Symptom Rating Scale. Can J Neurol Sci1980;7:233.
10.
Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. Washington (DC): American Psychiatric Association; 1992.
11.
GuyW.ECDU assessment manual for psychopharmacology. Washington (DC): Department of Education and Welfare; 1976.
12.
SimpsonGMAngusJ.A rating scale for extrapyramidal side effects. Acta Psychiatr Scand1970;112 (Suppl):11S–19S.
13.
BarnesTRE. A rating scale for drug-induced akathisia. Br J Psychiatry1989;154:672–6.
14.
CaligiuriMLohrJBJesteDV. Parkinsonism in antipsychotic-naïve schizophrenic patients. Am J Psychiatry1993;150:1343–8.
15.
ChouinardGJonesBRemingtonGBloomDAddingtonDMacEwanGW, and others. A Canadian multicentre, placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenia patients. J Clin Psychopharmacol1993;13:25–40.
16.
SimpsonGMLindenmayerJP. Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol1997;17:194–201.
17.
CaseyDE. Side effect profiles of the new antipsychotic agents. J Clin Psychiatry1996;57(2 Suppl):40S–45S.
18.
GoldbergD.Antipsychotics for dementia-related behavioral disturbances in elderly institutionalized patients. Clin Geriatr1996;4:1–6.
19.
LiebermanJA. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: A rationale and hypothesis. J Clin Psychiatry1996;57(11 Suppl):.
20.
KopalaLCFredericksonDGoodKPHonerWG. Symptoms in neuroleptic-naïve, first-episode schizophrenia: Response to risperidone. Biol Psychiatry1996;39:296–8.
21.
Bezchlibnyk-ButlerKZJeffriesJL, editors. Clinical handbook of psychotropic drugs. 5th ed.Gottingen, Germany: Hogrefe and Huber Publishers; 1995.
22.
Van KammenDPMarderSR. Clozapine. In: KaplanHSadockB, editors. Comprehensive Textbook of Psychiatry. 6th ed.Volume 2. Baltimore: Williams & Wilkins; 1995. p 1979–87.
23.
CaseyDE. Neuroleptic-induced acute extrapyramidal syndrome and tardive dyskinesia. Psychiatric Clin North Amer1993;16:589–610.
24.
BraudeWMBarnesTREGoldSM. Clinical characteristics of akathisia: A systematic classification of acute psychiatric inpatient admissions. Br J Psychiatry1983;143:139–50.
25.
FleischhackerWWRothSDKaneJM. The pharmacologic treatment of antipsychotic-induced akathisia. J Clin Psychopharmacol1990;10:12–21.
26.
KaneJMWoernerMKleinholdP.Incidence of tardive dyskinesia: Five-year data from a prospective study. Psychopharmacol Bull1984;20:387–9.
27.
KaneJMWoernerMBorensteinM.Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull1986;22:54–8.
28.
WoernerMKaneJMLeibermanJ.The prevalence of tardive dyskinesia. J Clin Psychopharmacol1991;1:34–42.
29.
KaneJMWoernerMPollockSLiebermanJ.Does clozapine cause tardive dyskinesia?J Clin Psychiatry1993;54:327–32.
30.
MarderSR. Risperidone, clinical development: North American results. Clin Neuropharmacol1997;15:92A–93A.
31.
BeasleyCMJrTollefsonGTranPSatterleeWSangerT.Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacol1996;14:11–23.
32.
ThakesGKNguyenJAStraussME. Clonazepam treatment of tardive dyskinesia: A practical GABAergic strategy. Am J Psychiatry1990;147:445–51.
33.
ShriquiCLAnnableL.Tadive dyskinesia. In: ShriquiCLNasrellahHA, editors. Contemporary issues in the treatment of schizophrenia, Washington (DC): American Psychiatric Press; 1995. p 585–632.
34.
BymasterFPHemrick-LuecheSKPerryKWFullerRW. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacol1996;124:87–94.
35.
BilderRMTurkelELipshutz-BrochLLiebermanJA. Antipsychotic medication effects on neuropsychological functions. Psychopharmacol Bull1992;28:353–66.
36.
MacPhersonRDoubleDBRowlandsRPHarrisonDM. Long-term psychiatric patients' understanding of antipsychotic medication. Hosp Community Psychiatry1993;44:71–3.
37.
BaldesseriniRJ. Drugs and the treatment of psychiatric disorders. In: GilmanAGRuhlTWNeisAS, editors. The pharmacological basis of therapeutics. 8th ed.New York: Pergomon; 1990. p 383–414.
38.
WirshingDAMarderSRGoldsteinD, and others. Novel antipsychotics: Comparison of weight gain liabilities. Presented at the 36th Annual Meeting of the American College of Neuropsychopharmacology; 1997 Dec 8–12; Kamuela, HI.
39.
PeuskensT.Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry1995;166:712–26.
40.
RischSCGroomGPJanowskiDS. Interfaces of psychopharmacology and cardiology: Part 2. J Clin Psychiatry1981;42:47–59.
41.
American Psychiatric Association Task Force Report 27: Sudden death in psychiatric patients: The role of neurolepic drugs. Washington (DC): American Psychiatric Association; 1987.
42.
LevinsonDFSimpsonGM. Serious non-extrapyramidal adverse effects of neuroleptics: Sudden death, agranulocytosis and hepatotoxicity. In: MeltzerMY, editor. Psychopharmacology: The third generation of progress. New York: Raven Press; 1987. p 1431–6.
